Table 2B. Relationship between KPNA2 expression and clinicopathological parameters in patients who received adjuvant therapy.
|
KPNA2 |
||||
|---|---|---|---|---|
| Parameters | Negative, N (%) | Positive, N (%) | χ2 | P-value |
|
Age (years) | ||||
| <50 | 83 (36.9) | 142 (63.1) | 7.67 | 0.006 |
| ⩾50 | 186 (48.4) | 198 (51.6) | ||
|
Size (cm) | ||||
| ≤1.5 | 69 (60.5) | 45 (39.5) | 15.03 | <0.001 |
| >1.5 | 201 (40.5) | 295 (59.5) | ||
|
Stage | ||||
| 1 | 97 (37.6) | 161 (62.4) | 11.64 | 0.003 |
| 2 | 142 (51.8) | 132 (48.2) | ||
| 3 | 31 (39.7) | 47 (60.3) | ||
|
Grade | ||||
| 1 | 21 (84.0) | 4 (16.0) | 97.69 | <0.001 |
| 2 | 110 (74.3) | 38 (25.7) | ||
| 3 | 139 (31.8) | 298 (68.2) | ||
|
Tubules | ||||
| 1 | 4 (57.1) | 3 (42.9) | 23.42 | <0.001 |
| 2 | 97 (59.5) | 66 (40.5) | ||
| 3 | 164 (37.7) | 271 (62.3) | ||
|
Pleomorphism | ||||
| 1 | 2 (66.7) | 1 (33.3) | 58.12 | <0.001 |
| 2 | 100 (71.4) | 40 (28.6) | ||
| 3 | 162 (35.1) | 299 (64.9) | ||
|
Mitosis | ||||
| 1 | 88 (81.5) | 20 (18.5) | 117.77 | <0.001 |
| 2 | 62 (65.3) | 33 (34.7) | ||
| 3 | 115 (28.6) | 287 (71.4) | ||
|
NPI | ||||
| Excellent | 2 (100) | 0 | 48.07 | <0.001 |
| Good | 20 (100) | 0 | ||
| Moderate 1 | 105 (51.2) | 100 (48.8) | ||
| Moderate 2 | 92 (42.0) | 127 (58.0) | ||
| Poor | 46 (35.7) | 83 (64.3) | ||
| Very poor | 5 (14.7) | 29 (85.3) | ||
|
Tumour type | ||||
| Invasive ductal/NST | 166 (37.4) | 278 (62.6) | 52.35 | <0.001 |
| Lobular | 22 (78.6) | 6 (21.4) | ||
| Atypical medullary | 2 (12.5) | 14 (87.5) | ||
| aMixed | 75 (65.8) | 39 (34.2) | ||
| bOther | 2 (100) | 0 | ||
Abbreviations: KPNA2=karyopherin α-2; NPI=Nottingham Prognostic Index; NST=no special type.
a
Lobular or tubular mixed breast cancers.
b
Mucinous, alveolar lobular, miscellaneous including metaplastic, adenoid cystic, spindle and tubulolobular.